{{ s.tag }}
{{ s.title }}
{{ s.body }}
{{ s.hrefLabel }} ↗A large short-term effect on axial elongation, an incomplete long-term safety record, and an unresolved rebound question. This node keeps those three separate rather than merging them into one claim.
What is proposed, and what remains a proposal.
The therapy delivers repeated, short sessions of low-level red light at around 650 nm directly into the eye through a desktop device used at home under supervision. The proposed mechanisms centre on choroidal response and on signalling pathways that modulate ocular growth.
Mechanism is where this node is weakest, and the honest description says so. The clinical trials measured outcomes — axial length and refraction — rather than the causal pathway. A treatment effect observed over twelve months does not identify the mechanism that produced it, and the reviews that summarise the field describe the mechanistic account as incomplete.
Measured light output differs between commercially available instruments. Anything written about exposure, dose or safety belongs to the device that was measured, not to red light as a category.
The trial that defines the effect size, with the design features that limit it stated in the same view.
Axial elongation of 0.13 mm in the treated group against 0.38 mm in the control group over twelve months, an absolute difference of −0.26 mm. Spherical equivalent changed −0.20 D against −0.79 D, an absolute difference of 0.59 D.
No sham arm and a single-blind design. Twelve months of follow-up. A Chinese cohort of East Asian children, which limits transferability to European populations. Device and dose are decisive and specific to the instrument used.
Absolute axial differences against each trial's own control arm, over that trial's own duration. These are not points on a shared scale and they do not rank products.
A randomised trial has compared repeated low-level red light directly against low-dose atropine for efficacy. That comparison tested which arm slowed progression more; it did not test the two used together. Why concurrent use requires special attention →
One randomised trial added red-light therapy to orthokeratology in children who had already responded poorly to orthokeratology alone. Axial length changed −0.02 mm in the combined group against 0.27 mm on orthokeratology alone over twelve months.
Forty-eight children were randomised 2:1 and forty-seven were analysed. The population was defined by prior poor response, which is not a general first-line group, and the sample cannot support a broader conclusion.
Three findings coexist. Reading any one of them alone gives the wrong picture.
{{ s.body }}
{{ s.hrefLabel }} ↗Device instructions for use list a dilated pupil and the use of medicines such as atropine among the contraindications. Radiometric measurement shows that radiant power entering the eye rises with pupil diameter for the same device output. Open the safety node →
Monitoring is not an add-on to this therapy. The safety review notes that structural monitoring was applied variably across the studies included, which is itself a limitation of the evidence base.
Intervals should be defined before treatment starts, not reconstructed afterwards, and axial biometry should be repeated under comparable conditions so that a rate — not a single value — can be read.
READ AN AXIAL LENGTH IN THE LAB →For atropine, rebound after cessation has been measured and is concentration-dependent — the three-year LAMP continuation and washout phase reports it directly. For repeated low-level red light, no equivalent washout evidence of comparable length exists, and no agreed tapering protocol follows from the published trials.
The three-year trial included continuation and washout phases and reported rebound as concentration-dependent. Higher concentrations showed greater rebound; 0.01% showed the least.
PMID 34627809 ↗The safety review reports a median follow-up of nine months across twenty studies, with twenty-four months as the longest. Cessation behaviour beyond that horizon is not established, so tapering remains a clinical judgement rather than a protocol.
EVIDENCE INSUFFICIENT / EVOLVINGWhat a future trial would have to answer before this node moves out of the emerging tier.
Krótkowzroczność.pl holds the complete Polish-language treatment of red-light therapy, including the Polish availability landscape and the clinical commentary. This node is an international synthesis of the same source material, not a translation of it.
EXPLORE THE FULL EVIDENCE NODE ↗